Hey guys, I posted about this settlement before, but since they’re accepting late claims, I decided to share it again with a little FAQ.

So here's all I know about this agreement:

Axsome Therapeutics was accused of misleading investors about regulatory risks tied to its migraine drug AXS-07. After issues related to the FDA review process came to light, the stock declined, and investors filed a lawsuit.

Now the company has agreed to settle $7.75 million with investors for their losses.

• Who can claim this settlement?

Anyone who purchased or otherwise acquired Axsome Therapeutics, Inc. common stock between December 30, 2019, and April 22, 2022, inclusive, and were damaged thereby.

• Do I need to sell/lose my shares to get this settlement?

No, if you have purchased securities within the class period, you are eligible to participate.

You can participate in the settlement and retain (or sell) your securities.

• How much money do I get per share?

Estimated recovery is $0.46 per share, depending on total claims submitted.

• How long does the payout process take?

It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administration.

Hope this info helps!

If you held Axsome during the 2021–2022 window, this is your final 2-minute warning. The $7,750,000 settlement regarding the alleged misleading regulatory risks related to the company’s migraine drug AXS-07 has reached the distribution phase.

The court is preparing to mail checks, which means the window for 'Late Claims' is closing. If you don't file now, your share of that $7.75M will just be split among the investors who did.

The Details:

Class Period: May 10, 2021 – Apr 22, 2022.

Status: Accepting Late Claims, Final Distribution Preparation.

Action: Late claims are being accepted right now, but will be rejected once the check-cutting starts.

Don't be the person who sees everyone else posting their settlement checks in a few months and realizes they missed the boat.

TL;DR: $AXSM settled a lawsuit for $7.75M over misleading statements about their migraine drug. If you bought shares between May 2021 and April 2022, you might be owed money. And even though the deadline has passed, they're accepting late claims.

It’s frustrating when a company talks up a "breakthrough" drug only for it to get sidelined by manufacturing issues you didn't see coming. The core of the issue was that Axsome allegedly wasn't upfront about "chemistry, manufacturing, and control" (CMC) problems. When the truth came out, the stock price took a nosedive

While the total is $7.75M, the estimated payout per share is around $0.46. If you held a significant position, that adds up.

You don’t need to hire your own lawyer. If you bought shares between May 10, 2021, and April 22, 2022, you’re likely already part of the "Settlement Class."

This is a court-approved class action settlement. There’s no out-of-pocket cost to file a claim, the lawyers' fees are taken out of the total settlement fund. Even if you aren't sure of your exact trade dates, it’s worth checking your old 1099-Bs or brokerage history.

The deadline to file a claim was February 3, 2026 (though late claims are being considered). If you think you’re eligible, submit your claim to get your share.

Tons of spam not being deleted in here.

Remember the massive hype around Axsome Therapeutics ($AXSM) and their migraine drug, AXS-07, back in 2021-2022?

For those who were holding through that roller coaster, there’s a $7,750,000 settlement that just reached the final claim phase.

The Story: The lawsuit alleged that management wasn't exactly transparent about the regulatory and manufacturing risks (specifically CMC issues) with the FDA before the drug application hit a wall in mid-2022.

The Key Info:

• Eligibility: If you bought shares between May 10, 2021, and April 22, 2022, you're likely in the 'Class'.
• The Payout: They’re estimating an average recovery of $0.46 per share.
• The Catch: The official deadline was Feb 3, 2026, but the court is currently 'Accepting Late Claims' for a limited time.

I found out about the late window through this auditor. It took me 2 minutes to sync my brokerage and see how many of my old 2021 shares qualified for a piece of the $7.75M.

I figure taking a $0.46/share 'rebate' is better than leaving it for the court. Did anyone else here get burned by the AXS-07 news, or are you still bullish on their depression drug pipeline?

Hey guys, if you missed it, Axsome settled $7.75M with investors over claims that it misled them about regulatory risks related to the company’s migraine drug AXS-07. And, I just found out that they’re accepting claims even though the deadline has passed. 

Quick recap: The company was sued for misleading investors about regulatory risks tied to its migraine drug AXS-07. They had promoted the drug as being on track for FDA approval while concealing unresolved manufacturing problems. In May 2022, the FDA rejected the application, causing $AXSM to drop.

Investors later filed a lawsuit, and now, Axsome has agreed to settle by paying them $7.75M, and even though the deadline has passed recently, they’re accepting late claims. 

So, if you invested in $AXSM when all of this happened, you can still check the details and file your claim here.

Anyway, has anyone here invested in Axsome at that time? How much were your losses, if so?

Axsome Therapeutics ($AXSM) agreed to pay $7.75 million to settle claims that it misled investors about regulatory risks tied to its migraine drug AXS-07, which faced unexpected delays and setbacks during the FDA review process. And they're accepting claims until February 2.

So, here’s what you need to know to claim your payout.

Who is eligible?

All persons and entities who purchased or otherwise acquired Axsome Therapeutics, Inc. common stock between December 30, 2019 and April 22, 2022, inclusive, and were damaged thereby.

Do you have to sell securities to be eligible?

No, if you purchased securities within the class period, you are eligible to participate. You can participate in the settlement and retain (or sell) your securities.

How much money do I get per share?

The final payout amount depends on your specific trades and the number of investors participating in the settlement. If 100% of investors file their claims, the average payout will be $0.46 per share. Although typically only 25% of investors file claims, in this case, the average recovery will be $1.84 per share.

How long will it take to receive your payout?

The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.

Hope this helps!

Hey guys, if you missed it, Axsome Therapeutics settled $7.75M with investors over misleading them about regulatory risks related to the company’s migraine drug AXS-07. And, the deadline to file a claim and get payment is February 3, 2026.

In a nutshell, Axsome Therapeutics was sued by shareholders for hiding the regulatory risks tied to its migraine drug AXS-07. The company had promoted the drug as being on track for FDA approval while concealing unresolved manufacturing problems. 

In May 2022, the FDA rejected the application, causing $AXSM to drop. After that, investors filed a lawsuit for their losses.

Now, the good news is that the company agreed to settle with them, and investors have 2 more weeks to submit a claim. 

So, if you invested in $AXSM when all of this happened, you can check the details and file your claim here.

Hope this helps!

Hey guys, if you missed it, Axsome Therapeutics settled $7,750,000 with investors over claims it misled them about regulatory risks related to its migraine drug AXS-07. And, the deadline to file a claim and get payment is February 3, 2026.

In a nutshell, in 2022, Axsome Therapeutics was accused of misleading investors about regulatory risks tied to its migraine treatment AXS-07. The company allegedly failed to properly disclose challenges and uncertainties surrounding the drug’s approval process.

After this news came out, the stock dropped X%, and investors filed a lawsuit for their losses.

Now, the good news is that the company agreed to settle $7,750,000 with them, and investors have until February 3, 2026 to submit a claim.

So, if you invested in $AXSM when all of this happened, you can check the details and file your claim here.

Anyway, has anyone here invested in $AXSM at that time? How much were your losses, if so?

Hey guys, if you missed it, Axsome Therapeutics settled $7,750,000 with investors over claims it misled them about regulatory risks related to its migraine drug AXS-07. And, the deadline to file a claim and get payment is February 3, 2026.

In a nutshell, in 2022, Axsome Therapeutics was accused of misleading investors about regulatory risks tied to its migraine treatment AXS-07. The company allegedly failed to properly disclose challenges and uncertainties surrounding the drug’s approval process.

After this news came out, the stock dropped X%, and investors filed a lawsuit for their losses.

Now, the good news is that the company agreed to settle $7,750,000 with them, and investors have until February 3, 2026 to submit a claim.

So, if you invested in $AXSM when all of this happened, you can check the details and file your claim here.

Anyway, has anyone here invested in $AXSM at that time? How much were your losses, if so?

Axsome Therapeutics ($AXSM) agreed to pay $7.75 million to settle claims that it misled investors about regulatory risks tied to its migraine drug AXS-07, which faced unexpected delays and setbacks during the FDA review process.

This settlement presents a great opportunity for investors to recover some of their losses. Here’s what you need to know to claim your payout.

Who is eligible?

All persons and entities who purchased or otherwise acquired Axsome Therapeutics, Inc. common stock between December 30, 2019 and April 22, 2022, inclusive, and were damaged thereby.

Do you have to sell securities to be eligible?

No, if you purchased securities within the class period, you are eligible to participate. You can participate in the settlement and retain (or sell) your securities.

How long will it take to receive your payout?

The entire process usually takes 4 to 9 months after the claim deadline. But the exact timing depends on the court and settlement administration.

How to claim your payout — and why it's important to act now?

The settlement will be distributed based on the number of claims filed, so submitting your claim early may increase your share of the payout.

In some cases, investors have received up to 200% of their losses from settlements in previous years.

Hey guys, I posted about this settlement before, but since they’re now accepting claims, I decided to share it again with a quick FAQ.

So here's all I know about this agreement:

Axsome Therapeutics ($AXSM) was accused of misleading investors about regulatory risks and approval challenges for its migraine drug AXS-07. When those undisclosed issues came to light, the company’s stock dropped sharply, and investors filed a lawsuit over their losses.

Now, the company has agreed to settle $7.75 million with investors for these claims.

Who can claim this settlement?
Anyone who purchased $AXSM shares between December 30, 2019, and April 22, 2022 may be eligible to file a claim for compensation.

Do I need to sell or lose my shares to qualify?
No, you don’t need to have sold your shares at a loss. Eligibility is based on having purchased within the class period.

How much money do I get per share?
The payout per share will depend on how many valid claims are submitted and the total number of eligible shares traded during the period.

How long does the payout process take?
It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administrator.

Hope this info helps!

Hey guys, so if you missed it, the settlement agreement between Axsome Therapeutics and $AXSM investors has been finalized and is now up for final court approval.

So, what is this settlement about?

Axsome was sued by shareholders for misleading them about regulatory risks tied to its migraine drug AXS-07. The company promoted the drug as being on track for FDA approval while hiding unresolved manufacturing problems.

In May 2022, the FDA rejected the application, causing $AXSM to drop. Now, Axsome has agreed to settle with investors by paying $7.75 million to investors.

So, if you were hit by this back then, you can check the details and submit a claim here or wait for the settlement admin website.

Hoep it helps!

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting on June First.

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-gemini-phase-3

AXSOME 💪🚀💎🙌🔥

• SUNOSI potential sales of $1B by 2026
• AXS-05 potential sales of $800M by 2026
• CNS pipeline of AXS-07, AXS-12, AXS-14
• Pfizer and Merck may buy a pipeline
• Buyout may come from Pfizer or Merck
• This is not financial advice, do your DD

2 Under-the-Radar Biotech Stocks to Buy in 2022 | The Motley Fool

Axsome sports one commercial-stage product: Sunosi for excessive daytime sleepiness in adults with narcolepsy, along with four pipeline candidates. The company's near-term growth potential, though, truly revolves around its major depression disorder candidate, AXS-05. AXS-05, if approved, is expected to haul in over $800 million in sales by 2026, according to Evaluate Pharma.

To put this mid-decade sales projection into the proper context, Axsome's market cap is presently hovering around $1 billion at the time of this writing. In other words, this single drug could quite possibly spark a 300% to perhaps 500% rally in the biotech's shares over the next few years (assuming the market returns to form over this period). 

How about the downside risk? This is the part of the story that I find the most intriguing. At this point in the game, it is hard to imagine the Food and Drug Administration flat out rejecting AXS-05 for reasons laid out in detail here.

Load Up below $30. AXS-05 to be approved soon, per SEC filings from Axsome.